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Acute gain 1.380.37 1.430.26 0.21 1.360.37 1.370.32 0.77
Late loss 0.220.32 0.540.49 <0.0001 0.250.27 0.460.44 <0.0001
Binary
restenosis
rate
3.3% 12.4% 0.01 5.5% 9.3% 0.26
Death 0 0 - 1 (0.7%) 1 (0.8%) -
Myocardial
Infarction
3 (2.5%) 0 - 0 1 (0.8%) -
TLR 3 (2.5%) 15 (11.6%) 0.007 8 (4.9%) 10 (7.8%) 0.34
TVR 8 (6.7%) 21 (16.2%) 0.03 19 (11.8%) 11 (8.5%) 0.43
Any MACE 9 (7.6%) 21 (16.2%) 0.05 20 (12.4%) 13 (10.0%) 0.58
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMConclusions: EES showed better clinical angiographic ﬁnding in the analysis of target
lesions in diabetic patients with small coronary artery diseases.
TCT-193
Effect Of Drug-Eluting Stents Versus Bare-Metal stents On Long-Term
Mortality Following Rotational Atherectomy For Complex Calciﬁc Coronary
Lesions
M Bilal Iqbal1, Tito Kabir1, Andrew Archbold2, Tom Crake3, Sam Firoozi4,
Sundeep S. Kalra5, Charles Knight2, Pitt Lim4, Iqbal S. Malik6, Anthony Mathur2,
Pascal Meier3, Roby Rakhit7, Simon Redwood8, Mark Whitbread9, Dan Bromage2,
Krishnaraj Rathod2, Andrew Wragg2, Philip A. MacCarthy5, Miles C. Dalby1
1Hareﬁeld Hospital, Royal Brompton and Hareﬁeld NHS Foundation Trust,
Middlesex, United Kingdom, 2The London Chest Hospital, Barts and The London
NHS Trust, London, United Kingdom, 3The Heart Hospital, University College
London NHS Foundation Trust, London, United Kingdom, 4St Georges' Hospital, St
Georges' Hospital NHS Trust, London, United Kingdom, 5King's College Hospital,
King's College Hospital NHS Foundation Trust, London, United Kingdom,
6Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom,
7Royal Free Hospital, Royal Free London NHS Foundation Trust, London, United
Kingdom, 8St Thomas' Hospital, Guys and St Thomas' Hospitals NHS Foundation
Trust, London, United Kingdom, 9London Ambulance Service, London, United
Kingdom
Background: Rotational atherectomy (RA) facilitates delivery of stents in calciﬁc
lesions. Calciﬁed coronary lesions are an established risk factor for long-term failure
after both bare metal stents (BMS) and drug-eluting stent (DES) implantation. Whilst
DES use following RA may result in high procedural success and acceptable reste-
nosis rates, there is limited data on their long-term efﬁcacy and prognostic beneﬁt
when used with RA.
Methods: We examined an observational cohort of 661 consecutive patients treated
with RA between 2005-2011 at 8 tertiary cardiac centers across London, UK.
Multivariate Cox-proportional hazards models using forward stepwise variable
selection were used to determine independent predictors of mortality.
Results: 209 patients (32%) were treated with BMS and 452 patients (68%) were with
DES. Patients in the BMS group were older (75.5y vs. 73.2y, p¼0.002). The fema-
le:male ratio; presence of cardiogenic shock; presence of diabetes; previous PCI and
CABG was similar between both groups. A greater proportion of patients in the BMS
group had ACS. GP 2b-3a inhibitor use was greater in the BMS group. The length of
stented segment was greater in the DES group (24mm vs.28mm, p<0.001). Multi-
variate analysis identiﬁed the use of DES as an independent predictor of 1-year
mortality (HR¼0.45, 95% CI: 0.26-0.78, p¼0.005) and 3-year mortality (HR¼0.64,
95% CI: 0.42-0.98, p¼0.041).JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr
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RA in the DES era with long-term follow-up. The use of DES following RA appears
to be associated with reduced long-term mortality.
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Background: Diabetes mellitus is associated with an increased risk of major adverse
cardiac events (MACE) following percutaneous coronary intervention. We compared
5-year clinical outcomes in patients with and without diabetes mellitus treated with the
second-generation zotarolimus-eluting Endeavor stent (E-ZES) or the ﬁrst-genera-
tion sirolimus-eluting Cypher Select+ stent (C-SES).
Methods: We randomised 2,332 patients to treatment with E-ZES (n¼1,162, dia-
betes: n ¼ 169) or C-SES (n ¼ 1,170, diabetes: n¼168) and followed them for 5
years. Randomisation was stratiﬁed by presence/absence of diabetes. MACE was
deﬁned as a composite of cardiac death, myocardial infarction, or target vessel
revascularization.
Results: In diabetic patients, use of E-ZES compared with C-SES was associated with
an increased risk of MACE (28.4% vs. 18.5%; hazard ratio (HR) ¼ 1.75, 95%
conﬁdence interval (CI): 1.05-2.93). In comparison, patients without diabetes had
similar 5-year MACE (15.0% vs. 15.1%, HR ¼ 0.99, 95% CI: 0.77-1.17).
Conclusions: Implantation of E-ZES as compared to C-SES is associated with an
increased risk of MACE in patients with diabetes at 5-year follow-up. This difference
was not observed in patients without diabetes.
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Background: Total stent length (TSL) after ﬁrst generation drug-eluting stents (DES)
implantation was associated with adverse cardiac events. However, it remains unclear
whether TSL after newer-generation DES implantation has impacts on clinical
outcomes. Our aim was to assess the relationship between TSL and clinical outcomes
after the Nobori biolimus-eluting stent (BES) and the Xience/Promus everolimus-
eluting stent (EES) implantation.
Methods: A total of 2284 patients with 3097 lesions undergoing BES (1269
patients with 1751 lesions) and EES (1015 patients with 1346 lesions) implantation
between February 2010 and July 2012 were analyzed. Patients and Lesions were
divided into quartile groups: TSL per patient (PA: 8 to 18 mm [n ¼ 814], PB: 19 to
24 mm [n ¼ 384],　PC: 25 to 42 mm [n ¼ 557], PD: 43 to 134 mm [n ¼ 529]), and
TSL per lesion (LA: 8 to 18 mm [n ¼ 1147], LB: 19 to 24 mm [n ¼ 547], LC: 25 to
38 mm [n ¼ 638], LD: 39 to 134 mm [n ¼ 765]). In the BES and EES groups, we
assessed the cumulative 1-year incidence of clinically driven target lesion revas-
cularization (TLR) and deﬁnite stent thrombosis based on TSL per patient and
lesion groupings, and cardiac death and myocardial infarction in the TSL per
patient groups.
Results: In per-lesion data, longer TSL increased TLR rates (p ¼ 0.0001) but did
not increased rate of stent thrombosis (p ¼ 0.11) in the BES group. In contrast,
longer TSL did not increased TLR rate (p ¼ 0.22) and rate of stent thrombosis (p ¼
0.45) in the EES group. In group LA, the rate of TLR was signiﬁcantly lower in the
BES group than in the EES group (3.1% vs.4.6%, p ¼ 0.005). In per-patient data,
longer TSL increased TLR rates (p ¼ 0.008) but did not increased rate of stent
thrombosis (p ¼ 0.74) in the BES group, whereas did not increased TLR rate (p ¼
0.24) and rate of stent thrombosis (p ¼ 0.38) in the EES group. Incidence of cardiac
death and myocardial infarction also did not increased with increasing TSL in the
two groups.
Conclusions: TSL per patient and lesion has signiﬁcantly impacts on TLR rates in the
BES group, whereas do not in the EES group. TSL per patients and lesion do not
increase the rate of stent thrombosis within 1-year in the BES and EES groups.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B63
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